Pull to refresh
Logo
What Changed
Following Why Sign Up
Daiichi Sankyo

Daiichi Sankyo

Pharmaceutical company

Appears in 5 stories · Last updated Oct 24, 2026

Stories

NICE approves Enhertu for HER2-low breast cancer after pricing rule change

Rule Changes

Discoverer and co-developer of Enhertu

The National Institute for Health and Care Excellence published final guidance on October 7, confirming that about 1,000 people a year in England can get Enhertu for HER2-low advanced breast cancer. The decision ended a 26-month dispute over price, after the UK raised what it will pay per quality-adjusted life year from £30,000 to £35,000.

Updated Oct 24

AstraZeneca invests $2 billion in Summit Therapeutics for ADC combination strategy

Money Moves

Clinical collaborator with AstraZeneca and Summit on Datroway combinations

AstraZeneca closed its $2 billion Summit Therapeutics investment on October 5: a straight equity purchase with no royalties or milestones attached, according to Biotech Morning. The cash funds trials pairing Summit's ivonescimab, a bispecific antibody that blocks PD-1 and VEGF, with AstraZeneca's antibody-drug conjugates.

Updated Oct 21

AI agent team designs a lung-cancer drug in Stanford's virtual biotech

New Capabilities

As of October 2026: Independently validated the B7-H3 antibody-drug conjugate strategy

Stanford built a drug-discovery operation with 37,000 AI agents and no lab benches. The virtual biotech analyzed 55,984 clinical trials and proposed a lung-cancer therapy that a human pharmaceutical company matched months later.

Updated Oct 11

Merck, Daiichi withdraw US application for lung cancer ADC after FDA pushback

New Capabilities

As of September 2026: Co-developer and originator of the ADC technology

Merck and Daiichi Sankyo withdrew their US application for ifinatamab deruxtecan, an experimental antibody-drug conjugate for extensive-stage small cell lung cancer, an aggressive disease that has resisted most new treatments. The FDA had told the companies their Phase 2 data were not enough to support accelerated approval, and the bid was pulled on September 25.

Updated Sep 29

FDA approves Enhertu for early-stage HER2-positive breast cancer

New Capabilities

As of May 2026: Originator of trastuzumab deruxtecan; holder of the FDA approval

The U.S. Food and Drug Administration (FDA) cleared AstraZeneca and Daiichi Sankyo's Enhertu for two new uses in early-stage HER2-positive breast cancer in May 2026. The drug, already a standard for advanced disease, now enters the window where the goal is cure, not control.

Updated May 18